Randomised Trials in percutaneous treatment for structural heart disease

Randomised Trials in percutaneous treatment for structural heart disease

On this page you will find a list of randomised trials in percutaneous treatment for structural heart disease, published in some of the world's top cardiology and interventional cardiology journals.

13.1 - TAVI AND MITRAL CLIP

  • PARTNER: TAVR vs standard therapy – 2-year results
  • TAVI vs standard treatment: PARTNER – 3 years
  • TAVR vs standard care for inoperable aortic stenosis: PARTNER I: 5 years
  • PARTNER trial 2-year results: TAVR vs surgery
  • TAVR vs SAVR: PARTNER 1: 5 years
  • Transapical aortic valve implantation vs surgical replacement: STACCATO trial
  • Aortic balloon-expandable vs self-expandable valves: CHOICE
  • Balloon expandable vs self-expandable valves for TAVI: CHOICE - 1 year
  • US CoreValve High Risk Study
  • Surgical versus transcatheter aortic valve replacement in high-risk patients: CORE VALVE US study 3 years
  • TAVR vs. SAVR in intermediate risk patients: PARTNER 2
  • Surgical vs self-expanding transcatheter aortic valve replacement: 2-year outcomes
  • SAPIEN XT vs SAPIEN for TAVR of inoperable patients PARTNER IIB
  • TAVR versus SAVR for severe aortic valve stenosis: NOTION trial
  • TAVR versus SAVR for aortic stenosis: NOTION 2 years
  • Surgical or transcatheter aortic-valve replacement in intermediate risk patients: SURTAVI
  • Percutaneous repair or surgery for mitral regurgitation: Everest II 5 years

13.2 - CLOSURE FORAMEN OVALE

  • Closure foramen ovale: CLOSURE I
  • Percutaneous closure of patent foramen ovale to prevent recurrent embolism: PC Trial
  • Patent foramen ovale closure vs anticoagulation vs antiplatelets after stroke: CLOSE trial (Added in December 2017)
  • Patent Foramen Ovale closure or medical therapy: RESPECT longterm (Added in December 2017)
  • Patent Foramen closure vs Medical Therapy: REDUCE trial (Added in December 2017)
  • Percutaneous closure of patent foramen ovale: RESPECT

13.3 - CLOSURE LEFT ATRIAL APPENDAGE

  • Left atrial appendage closure for stroke prevention: PROTECT AF – 2.3 years
  • Left atrial appendage closure vs warfarin for atrial fibrillation: PROTECT AF 3.8 years
  • Left atrial appendage closure device: PREVAIL trial

13.4 - CLOSURE VENTRICULAR SEPTAL DEFECT

  • Transcatheter vs surgical closure ventricular septal defect

Access these randomised trials here

Sponsored by

Biotronik